AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35152218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline and fluctuating cognition
Number of subjects: 66
Study 35152218 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent falling
Number of subjects: 66
Study 35152295 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV viremia ≥ 1000 IU/mL in HEU children
Number of subjects: 1024
Study 35152295 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 1-log increase in CMV viral load in HEU children
Number of subjects: 1024
Study 35152295 — intervention group
Group type: COMPARATOR
Intervention: CMV viremia in HIV-unexposed children
Number of subjects: 1024
Study 35152857 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study 35152857 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 0
Study 35152886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezamizumab
Number of subjects: 7
Study 35152897 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic rendering
Number of subjects: 40
Study 35152897 — intervention group
Group type: COMPARATOR
Intervention: Weight support
Number of subjects: 40
Study 35152897 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with haptic rendering
Number of subjects: 40
Study 35152897 — intervention group
Group type: COMPARATOR
Intervention: Training with weight support
Number of subjects: 40
Study 35152897 — intervention group
Group type: COMPARATOR
Intervention: Training modalities
Number of subjects: 40
Study 35153091 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived PA83-FhCMB vaccine at doses of 12.5, 25, 50, or 100 µg with Alhydrogel®
Number of subjects: 0
Study 35153091 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived PA83-FhCMB vaccine
Number of subjects: 0
Study 35153096 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTIVE tool (MI-based communication tool)
Number of subjects: 2504
Study 35153154 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided radiation therapy (RT)
Number of subjects: 10
Study 35153205 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence exposure
Number of subjects: 276
Study 35153205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative effect of asthma morbidity
Number of subjects: 276
Study 35153205 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline violence exposure and depressive symptoms
Number of subjects: 276
Study 35153967 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Number of subjects: 52
Study 35153967 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment index (2 or more tests >1.5 SD below normative mean)
Number of subjects: 52
Study 35153967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraindividual variability in cognitive functioning
Number of subjects: 52
Study 35153967 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain injury symptom load
Number of subjects: 52
Study 35154096 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive interferon-α (IFN-α) therapy
Number of subjects: 9
Study 35154388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study 35154389 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 103
Study 35154390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES) for 10 minutes, 3 consecutive days in addition to Standard Logopaedic Therapy (SLT)
Number of subjects: 20
Study 35154390 — intervention group
Group type: COMPARATOR
Intervention: Standard Logopaedic Therapy (SLT) alone
Number of subjects: 20
Study 35154704 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard systemic treatment for mCRC
Number of subjects: 47
Study 35154830 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based treatment plans
Number of subjects: 15
Study 35154830 — intervention group
Group type: COMPARATOR
Intervention: CT-based treatment plans
Number of subjects: 15
Study 35155529 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and boiled potatoes intake
Number of subjects: 3401
Study 35155529 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato consumption
Number of subjects: 3401
Study 35155529 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries consumption
Number of subjects: 3401
Study 35155592 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional speckle tracking echocardiography (2D STE) combined with multiple circulating biomarkers and accurate heart dosimetry
Number of subjects: 104
Study 35155592 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 5-time points (baseline; after completion of RT; 2, 6, and 12 months after RT)
Number of subjects: 104
Study 35155599 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan add-on therapy
Number of subjects: 128
Study 35155599 — intervention group
Group type: COMPARATOR
Intervention: Loop diuretic treatment
Number of subjects: 128
Study 35155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge-Enhanced ACL Restoration (BEAR)
Number of subjects: 100
Study 35155707 — intervention group
Group type: COMPARATOR
Intervention: Autograft ACL Reconstruction (ACLR)
Number of subjects: 100
Study 35155859 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-FXI, 300 mg open-label dose
Number of subjects: 49
Study 35155863 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV D-RNA-positive/R-negative kidney transplantation (KT) followed by 8 weeks of glecaprevir/pibrentasvir (G/P) initiated 2 to 5 days post-KT
Number of subjects: 63
Study 35155863 — intervention group
Group type: COMPARATOR
Intervention: Matched waitlist comparators who did not opt-in to receive a kidney from an HCV-viremic donor
Number of subjects: 63
Study 35155982 — intervention group
Group type: EXPERIMENTAL
Intervention: SC+EP (standard care + enhanced program)
Number of subjects: 205
Study 35155982 — intervention group
Group type: COMPARATOR
Intervention: SC (standard care)
Number of subjects: 205
Study 35155984 — intervention group
Group type: EXPERIMENTAL
Intervention: LARGE-PACKAGE
Number of subjects: 30
Study 35155984 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 30
Study 35155983 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflatoxin exposure in pregnant women in Malawi
Number of subjects: 0
Study 35155983 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflatoxin exposure in pregnant women in Bangladesh
Number of subjects: 0
Study 35155983 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 0
Study 35155983 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 18-24 months
Number of subjects: 0
Study 35156036 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily (arm A)
Number of subjects: 48
Study 35156036 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily (arm B)
Number of subjects: 48
Study 35156036 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily (arm C)
Number of subjects: 48
Study 35156036 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib dose escalation to 160 mg
Number of subjects: 48
Study 35156068 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-19 (1.5 mg)
Number of subjects: 61
Study 35156068 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-19 (3.0 mg)
Number of subjects: 61
Study 35156068 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-19N (3.0 mg)
Number of subjects: 61
Study 35156068 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-19N
Number of subjects: 61
Study 35156190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine with/without azithromycin
Number of subjects: 476
Study 35156190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 476
Study 35156190 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction maps and reference charts
Number of subjects: 476
Study 35156195 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study 35156195 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat dosing of liso-cel
Number of subjects: 0
Study 35156421 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation candidates with mechanical circulatory support (MCS)
Number of subjects: 3
Study 35156421 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation candidates without mechanical circulatory support (MCS)
Number of subjects: 3
Study 35156421 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidates ineligible for heart transplantation and scheduled for long-term mechanical circulatory support (MCS)
Number of subjects: 3
Study 35156451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tack-Optimized Balloon Angioplasty using the Tack Endovascular System
Number of subjects: 0
Study 35156451 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35156500 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-guided videoconferencing acceptance and commitment therapy (ACT) with psychoeducation
Number of subjects: 10
Study 35156500 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 35156519 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy with autophagy inhibition
Number of subjects: 0
Study 35156519 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard targeted therapy without autophagy inhibition
Number of subjects: 0
Study 35156709 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*13:02
Number of subjects: 1364
Study 35156709 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*15:02
Number of subjects: 1364
Study 35156709 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*15:01
Number of subjects: 1364
Study 35156709 — intervention group
Group type: COMPARATOR
Intervention: Anti-spike antibody titres
Number of subjects: 1364
Study 35157306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab plus HyperCVAD/HD-MA (O-HyperCVAD)
Number of subjects: 37
Study 35157313 — intervention group
Group type: EXPERIMENTAL
Intervention: Alopecia areata (AA)
Number of subjects: 5435
Study 35157371 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 305
Study 35157371 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg
Number of subjects: 305
Study 35157371 — intervention group
Group type: COMPARATOR
Intervention: Anifrolumab 150 mg
Number of subjects: 305
Study 35157505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G7 Continuous Glucose Monitoring
Number of subjects: 0
Study 35157764 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201
Number of subjects: 20
Study 35157764 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC206
Number of subjects: 20
Study 35157764 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of ONC201 and ONC206
Number of subjects: 20
Study 35157764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ONC201 and ONC206
Number of subjects: 20
Study 35157764 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipridone treatment
Number of subjects: 20
Study 35157769 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV) in treatment naïve (TN) CLL patients
Number of subjects: 0
Study 35157769 — intervention group
Group type: COMPARATOR
Intervention: Recombinant zoster vaccine (RZV) in patients receiving BTKi therapy
Number of subjects: 0
Study 35157769 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant positive humoral and cellular immune response in subjects with a humoral response
Number of subjects: 0
Study 35157769 — intervention group
Group type: COMPARATOR
Intervention: Concordant positive humoral and cellular immune response in subjects without a humoral response
Number of subjects: 0
Study 35157978 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 28 days) with Cetuximab and Radiotherapy
Number of subjects: 9
Study 35157988 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) models using random survival forest (RSF) method
Number of subjects: 14842
Study 35157988 — intervention group
Group type: COMPARATOR
Intervention: Traditional regression models
Number of subjects: 14842
Study 35158473 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a (Q2W)
Number of subjects: 0
Study 35158473 — intervention group
Group type: EXPERIMENTAL
Intervention: No PBH conversion
Number of subjects: 0
Study 35158473 — intervention group
Group type: EXPERIMENTAL
Intervention: NEDA achievement
Number of subjects: 0
Study 35158476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg over 2 years
Number of subjects: 482
Study 35158924 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with mEHT
Number of subjects: 210
Study 35158924 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy without mEHT
Number of subjects: 210
Study 35159082 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (ADT) + Docetaxel
Number of subjects: 250
Study 35159082 — intervention group
Group type: COMPARATOR
Intervention: Androgen-deprivation therapy (ADT) - Docetaxel
Number of subjects: 250
Study 35159082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ADT + Docetaxel and ADT - Docetaxel
Number of subjects: 250
Study 35159091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogenic alterations in histologically negative lymph nodes
Number of subjects: 0
Study 35160005 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels assessed during the first 24 hours of hospitalization
Number of subjects: 569
Study 35160005 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of long-term outcomes after 1 year
Number of subjects: 569
Study 35160097 — intervention group
Group type: EXPERIMENTAL
Intervention: Schmitz-Hinkelbein method
Number of subjects: 15
Study 35160097 — intervention group
Group type: COMPARATOR
Intervention: Cologne method
Number of subjects: 15
Study 35162152 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake (1939.1 kcal, 95% CI: 1926.9; 1951.3)
Number of subjects: 5994
Study 35162152 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure (1915.7 kcal, 95% CI: 1906.4; 1924.9)
Number of subjects: 5994
Study 35162152 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy imbalance gap (23.4 kcal, 95% CI: 11.9; 35.0)
Number of subjects: 5994
Study 35162152 — intervention group
Group type: COMPARATOR
Intervention: Energy imbalance gap in overweight and obese subjects from Argentina, Costa Rica, Ecuador, Peru, and Venezuela
Number of subjects: 5994
Study 35162298 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction with Internal Fixation (ORIF) of acetabular fractures
Number of subjects: 31
Study 35162337 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal values and life satisfaction assessment
Number of subjects: 953
Study 35162337 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Life Scale
Number of subjects: 953
Study 35162337 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 953
Study 35162379 — intervention group
Group type: EXPERIMENTAL
Intervention: B-SWELL program
Number of subjects: 0
Study 35162707 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression during lockdown
Number of subjects: 534
Study 35162786 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination enhancement group
Number of subjects: 120
Study 35162786 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination enhancement PLUS group (with caregivers in a parallel group)
Number of subjects: 120
Study 35162786 — intervention group
Group type: COMPARATOR
Intervention: Leisure activity group
Number of subjects: 120
Study 35162812 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 52
Study 35162827 — intervention group
Group type: EXPERIMENTAL
Intervention: ReStoreD intervention (8-week remotely administered dyadic intervention)
Number of subjects: 34
Study 35162827 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 34
Study 35164584 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' willingness to deprescribe if their physician agreed
Number of subjects: 0
Study 35164584 — intervention group
Group type: COMPARATOR
Intervention: Surrogates' belief in the necessity of all medications
Number of subjects: 0
Study 35164584 — intervention group
Group type: COMPARATOR
Intervention: Surrogates' attribution of cost as a factor in deprescribing
Number of subjects: 0
Study 35164584 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perception of medication burden
Number of subjects: 0
Study 35164682 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent endoscopic hemostasis
Number of subjects: 386
Study 35164682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prediction model
Number of subjects: 386
Study 35164682 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-curve analyses and clinical impact curve
Number of subjects: 386
Study 35164745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiometabolic diseases (CMD) group
Number of subjects: 791
Study 35164745 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins, ACE-I, ARBs, diabetes medications
Number of subjects: 791
Study 35164745 — intervention group
Group type: COMPARATOR
Intervention: Absence of treatment
Number of subjects: 791
Study 35164745 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO (Five) Well-Being Index (WHO-5)
Number of subjects: 791
Study 35164804 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative care cohort (combined somatic and mental health expertise)
Number of subjects: 1364
Study 35164804 — intervention group
Group type: COMPARATOR
Intervention: Standard care cohort (somatic expertise only)
Number of subjects: 1364
Study 35164804 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative care cohort
Number of subjects: 1364
Study 35164860 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ-positive cognitively normal (CN+) group
Number of subjects: 88
Study 35164860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plasma Aβ and gut microbiota
Number of subjects: 88
Study 35164860 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting the gut microbiota
Number of subjects: 88
Study 35164933 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 25567
Study 35164933 — intervention group
Group type: COMPARATOR
Intervention: No Proton Pump Inhibitors (Control)
Number of subjects: 25567
Study 35164991 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine
Number of subjects: 15294
Study 35164991 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15294
Study 35165100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib treatment
Number of subjects: 5
Study 35165100 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with sunitinib)
Number of subjects: 5
Study 35165103 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) at baseline and at the end of the first cycle of chemotherapy.
Number of subjects: 243
Study 35165103 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TOI ≤54
Number of subjects: 243
Study 35165103 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LCS ≤21
Number of subjects: 243
Study 35165103 — intervention group
Group type: EXPERIMENTAL
Intervention: Early changes in LCS and baseline LCS scores
Number of subjects: 243
Study 35165103 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment HRQoL scores
Number of subjects: 243
Study 35165103 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining HRQoL values
Number of subjects: 243
Study 35165110 — intervention group
Group type: EXPERIMENTAL
Intervention: Macro-scale estimators (17 health-related, socioeconomic, climatic, and political factors)
Number of subjects: 170
Study 35165110 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 170
Study 35165110 — intervention group
Group type: EXPERIMENTAL
Intervention: Best subsets regression
Number of subjects: 170
Study 35165110 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis for tuberculosis deaths
Number of subjects: 170
Study 35165236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (knowledge translation intervention)
Number of subjects: 25
Study 35165236 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 25
Study 35165421 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Number of subjects: 0
Study 35165764 — intervention group
Group type: EXPERIMENTAL
Intervention: Penpulimab intravenous infusion of 1, 3 and 10 mg/kg every 2 weeks in dose-escalation phase and 200 mg every 2 weeks in dose-expansion phase (Phase Ia/Ib trial in Australia).
Number of subjects: 67
Study 35165764 — intervention group
Group type: EXPERIMENTAL
Intervention: Penpulimab 200 mg every 2 weeks (Phase Ib/II trial in China).
Number of subjects: 67
Study 35166043 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation via flexible catheter
Number of subjects: 13
Study 35166065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily
Number of subjects: 151
Study 35166065 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib 100 mg once daily
Number of subjects: 151
Study 35166465 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg IV Q2W plus axitinib
Number of subjects: 488
Study 35166465 — intervention group
Group type: COMPARATOR
Intervention: Weight-based dosing of avelumab (10 mg/kg IV Q2W)
Number of subjects: 488
Study 35166713 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMray PanCan-d test
Number of subjects: 586
Study 35166713 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMray PanCan-d test (after excluding probable Lewis-null individuals)
Number of subjects: 586
Study 35166723 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD patients
Number of subjects: 15
Study 35166723 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 15
Study 35166929 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib 250 mg QD plus toripalimab 240 mg Q3W
Number of subjects: 30